Physician profile
James A Bledsoe
NPI 1669467544
$9,181.63
in general payments reported to CMS, 2019-2025
62 companies · $560 in 2025
The $560 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $1,083 · 2021: $1,764 · 2022: $1,787 · 2023: $1,534 · 2024: $1,550 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,644.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $823.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $758.63 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $665.93 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $643.46 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $642.14 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $627.23 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $577.26 | 2019-2025 | Repatha, Evenity, Otezla |
| Astellas Pharma US INC | $503.09 | 2020-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $447.85 | 2019-2025 | |
| Amarin Pharma, INC. | $244.68 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $218.55 | 2020-2024 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $205.90 | 2019-2024 | |
| Dexcom, INC. | $193.71 | 2020-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $188.76 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.73 | 2020-2024 | Trintellix |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bledsoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.